<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Parathyroidectomy in end-stage kidney disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Parathyroidectomy in end-stage kidney disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Parathyroidectomy in end-stage kidney disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mira Milas, MD, FACS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sally E Carty, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 07, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H30749376"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Parathyroid surgery in patients with end-stage kidney disease (ESKD) is an effective therapy for normalization or stabilization of calcium and parathyroid hormone (PTH) metabolism, and for improving renal osteodystrophy [<a href="#rid1">1-5</a>]. </p><p>Although the initial and predominant management of hyperparathyroidism (HPT) in ESKD is with medical therapy, approximately 10 percent of patients ultimately require surgery for ESKD-related HPT (sometimes referred to as renal HPT) [<a href="#rid6">6</a>]. Parathyroid surgery is also an effective therapy for patients with persistent HPT after renal transplantation [<a href="#rid7">7-15</a>].</p><p>The surgical techniques of parathyroidectomy in ESKD patients are discussed here. The medical management of HPT in patients with ESKD is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/7299.html" rel="external">"Kidney transplantation in adults: Persistent hyperparathyroidism after kidney transplantation"</a>.) </p><p class="headingAnchor" id="H30749383"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>Although medical therapies, including calcimimetics (eg, <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a>), have allowed some patients with end-stage kidney disease (ESKD) to be treated nonoperatively [<a href="#rid7">7-15</a>], symptomatic patients with markedly elevated parathyroid hormone (PTH) levels should be referred for parathyroid surgery if they become refractory to medical therapy. Preoperative hypocalcemia is a contraindication to surgery. The specific indications for parathyroidectomy in patients with ESKD are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/7299.html" rel="external">"Kidney transplantation in adults: Persistent hyperparathyroidism after kidney transplantation"</a>.)</p><p class="headingAnchor" id="H30749439"><span class="h1">SURGICAL ANATOMY</span><span class="headingEndMark"> — </span>Knowledge of both normal and variant patterns of parathyroid anatomy is essential to successful parathyroid surgery. Normal parathyroid anatomy is reviewed elsewhere (see  <a class="medical medical_review" href="/z/d/html/2156.html" rel="external">"Surgical anatomy of the parathyroid glands"</a>). Variant patterns of parathyroid anatomy seen in end-stage kidney disease (ESKD) patients are briefly discussed below. </p><p class="headingAnchor" id="H12708719"><span class="h2">Number and location of parathyroid glands</span><span class="headingEndMark"> — </span>Most ESKD patients with hyperparathyroidism (HPT) have four-gland enlargement. However, some glands may descend into deep retroesophageal or paratracheal spaces, which makes them difficult to discern [<a href="#rid16">16</a>]. Patients with ESKD may also have enlargement of ectopic parathyroid rests in the cervical thymus [<a href="#rid17">17</a>]. </p><p class="headingAnchor" id="H357399594"><span class="h2">Parathyroid gland features</span><span class="headingEndMark"> — </span>Compared with normal glands, parathyroid glands in ESKD patients have more nodularity with a preponderance of oxyphilic parathyroid cells, more fibrosis with a sclerosed architecture, and more dystrophic calcifications [<a href="#rid18">18,19</a>]. Such shape and texture changes obscure a clear vascular pedicle, which makes shaping a parathyroid remnant more difficult. </p><p>In ESKD patients, parathyroid glands can enlarge significantly (to 500 to 1000 mg per gland) but remain histologically hypercellular [<a href="#rid18">18,19</a>]. Single or double adenomas are rarely seen in ESKD patients [<a href="#rid20">20</a>] but have been reported in up to 24 percent of patients post-renal transplantation [<a href="#rid21">21</a>]. (See <a class="local">'Four-gland exploration'</a> below.) </p><p class="headingAnchor" id="H3048786118"><span class="h1">CHOOSING A SURGICAL TECHNIQUE</span><span class="headingEndMark"> — </span>Techniques of parathyroid surgery include:</p><p class="bulletIndent1"><span class="glyph">●</span>Targeted parathyroidectomy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sub- or near-total parathyroidectomy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Total parathyroidectomy with autotransplantation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Total parathyroidectomy without autotransplantation</p><p></p><p>The choice is dependent upon whether the surgery is primary or reoperative, whether the patient has an existing or planned renal transplant, and whether the patient has a compelling reason to avoid reoperative neck surgery.</p><p class="headingAnchor" id="H22524990"><span class="h2">For the initial parathyroid surgery</span><span class="headingEndMark"> — </span>Most end-stage kidney disease (ESKD) patients have multigland hyperplasia, for which a subtotal, near-total, or total parathyroidectomy is typically performed as the initial surgery  (<a class="graphic graphic_figure graphicRef107529" href="/z/d/graphic/107529.html" rel="external">figure 1</a>) [<a href="#rid22">22-24</a>]. Targeted parathyroidectomy is an option for the rare post-renal-transplant patients who present with single or double adenomas [<a href="#rid21">21</a>]. </p><p class="headingAnchor" id="H2319374743"><span class="h3">Patients with existing or planned renal transplant</span><span class="headingEndMark"> — </span>For patients with an existing or planned renal transplant, we suggest performing either a sub- or near-total parathyroidectomy, or a total parathyroidectomy with autotransplantation, rather than a total parathyroidectomy without autotransplantation. The choice further depends upon whether the patient has a compelling reason to avoid the possibility of a neck reoperation.</p><p>Total parathyroidectomy without autotransplantation should be avoided in this setting because it is associated with the highest risk of postoperative permanent hypocalcemia, which is more difficult to treat once the patient is no longer dialysis dependent after renal transplantation. </p><p>In a retrospective study of 105 kidney transplant recipients who underwent surgery for tertiary hyperparathyroidism, subtotal parathyroidectomy was associated with a lower incidence of hypoparathyroidism than total thyroidectomy with autotransplantation (23 versus 45 percent) [<a href="#rid25">25</a>]. The incidences of persistent or recurrent hyperparathyroidism were not statistically different between the two groups. Hypoparathyroidism can lead to graft kidney failure. </p><p class="headingAnchor" id="H2813041412"><span class="h4">Patients without contraindications to reoperative neck surgery</span><span class="headingEndMark"> — </span>For most patients who have no contraindications to reoperative neck surgery, we typically perform a sub- or near-total parathyroidectomy rather than a total parathyroidectomy with autotransplantation. </p><p>A sub- or near-total parathyroidectomy has a lower risk of postoperative permanent hypocalcemia because the remnant is attached to its original blood supply. Compared with an autograft supplied only by neovascularization, an anatomic parathyroid remnant is more resilient to ischemia and less likely to fail. (See <a class="local">'Subtotal parathyroidectomy'</a> below.)</p><p>However, the risk of neck recurrence is potentially greater in patients undergoing sub- or near-total rather than total parathyroidectomy (with autotransplantation), which may necessitate reoperations in the cervical area [<a href="#rid26">26,27</a>].</p><p class="headingAnchor" id="H3343107003"><span class="h4">Patients with compelling reasons to avoid reoperative neck surgery</span><span class="headingEndMark"> — </span>For patients who have a compelling reason to avoid the possibility of a neck reoperation, we prefer a total parathyroidectomy with autotransplantation, rather than a sub- or near-total parathyroidectomy. Examples of such reasons include thyroid conditions that potentially require additional surgical procedures, prior history of repeated neck surgery, known recurrent laryngeal nerve injury, significant medical comorbidities, or intolerance of general anesthesia.</p><p>Total parathyroidectomy with autotransplantation negates the risk of a major neck reoperation by relocating the surviving parathyroid remnant to a site where recurrent hyperparathyroidism (HPT) may be detected and treated more conveniently. However, there is an increased risk of temporary and permanent hypocalcemia. (See <a class="local">'Total parathyroidectomy with heterotopic autotransplantation'</a> below.)</p><p class="headingAnchor" id="H1229732470"><span class="h3">Patients excluded from renal transplant</span><span class="headingEndMark"> — </span>For patients excluded from renal transplant, we suggest performing a total parathyroidectomy without autotransplantation, rather than other procedures. In addition, patients who have calciphylaxis should also undergo total parathyroidectomy without autotransplantation [<a href="#rid28">28,29</a>]. Calciphylaxis is a serious disorder that most commonly occurs in ESKD patients. It is characterized by calcification of dermal arterioles and classically presents with skin ischemia and necrosis. (See  <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">"Calciphylaxis (calcific uremic arteriolopathy)"</a>.)</p><p>Patients excluded from renal transplantation require continued dialysis, which exposes them to a high risk of developing recurrent HPT. Total parathyroidectomy without autotransplantation is the most effective surgical treatment for severe refractory HPT in this group of patients [<a href="#rid30">30</a>]. (See <a class="local">'Total parathyroidectomy without autotransplantation'</a> below.) </p><p>Although patients undergoing total parathyroidectomy without autotransplantation have the highest risk of developing hypocalcemia, they can be supplemented with calcium during routine dialysis. </p><p class="headingAnchor" id="H3485801925"><span class="h2">For reoperative parathyroid surgery</span><span class="headingEndMark"> — </span>For patients who require reoperative parathyroid surgery, we prefer a targeted exploration of the recurrence sites, including the autograft site, guided by preoperative imaging and intraoperative parathyroid hormone (PTH) monitoring, rather than a blind bilateral neck exploration. (See <a class="local">'Reoperative parathyroid surgery'</a> below.)</p><p class="headingAnchor" id="H30749446"><span class="h1">SURGICAL TECHNIQUES</span><span class="headingEndMark"> — </span>Commonly used surgical techniques for treating hyperparathyroidism in end-stage kidney disease (ESKD) patients include subtotal/near-total parathyroidectomy and total parathyroidectomy with or without autotransplantation  (<a class="graphic graphic_figure graphicRef107529" href="/z/d/graphic/107529.html" rel="external">figure 1</a>). The choice of techniques is dictated by whether the patient is a candidate for a renal transplant as detailed above (see <a class="local">'Choosing a surgical technique'</a> above). Whenever feasible, a thymectomy and parathyroid tissue cryopreservation should be performed with the primary procedure.</p><p class="headingAnchor" id="H30749482"><span class="h2">General principles</span><span class="headingEndMark"> — </span>For ESKD patients with four enlarged glands, parathyroid surgery should be conducted in an orderly sequence as detailed below. </p><p class="headingAnchor" id="H3254532318"><span class="h3">Four-gland exploration</span><span class="headingEndMark"> — </span>First, all parathyroid glands should be exposed after a thorough bilateral neck exploration via a transverse cervical incision. Biopsy, capsular rupture, or fragmentation of the glands should be avoided to prevent parathyromatosis. </p><p class="headingAnchor" id="H2923052153"><span class="h3">Create a parathyroid remnant</span><span class="headingEndMark"> — </span>If a subtotal parathyroidectomy is planned, a parathyroid remnant should be created next, before any other gland is resected, so that the viability of the remnant can be monitored while the remaining glands are removed. Marking the remnant with a titanium clip facilitates its localization in the event of a reoperation. Alternatively, the remnant can be marked with a long permanent suture buried just below the strap muscles, to be traced back to the remnant during a reoperation.</p><p class="headingAnchor" id="H1714844237"><span class="h3">Search for the missing gland(s)</span><span class="headingEndMark"> — </span>In general, identification of fewer than four parathyroid glands in ESKD patients should prompt a search for the missing gland(s). The search should follow an organized and deliberate sequence, including searching the retroesophageal and deep paratracheal spaces, the carotid artery and jugular venous sheaths, potential intrathyroidal locations, and the thymus [<a href="#rid16">16,22</a>]. (See  <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">"Parathyroid exploration for primary hyperparathyroidism", section on 'Missing gland'</a>.)</p><p>Intrathyroidal parathyroid glands in ESKD patients can be sizeable and mimic thyroid nodules. If a thyroid nodule is suspected to be of parathyroid origin, parathyroid hormone (PTH) measurement of fluid obtained from the nodule by needle aspiration may be confirmatory [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H4264387098"><span class="h3">Cervical thymectomy</span><span class="headingEndMark"> — </span>If an inferior parathyroid gland is missing, it is most likely located in one of the intrathymic locations [<a href="#rid16">16</a>]. Thymectomy is an important component of parathyroid surgery for ESKD patients who have missing inferior parathyroid glands because retained intrathymic glands can be the source of persistent or recurrent disease [<a href="#rid17">17</a>]. In one study, adding a cervical thymectomy increased the overall cure rate of HPT from 89 to 94 percent [<a href="#rid32">32</a>]. </p><p>Cervical thymectomy must be performed with care. Many ESKD patients have friable cervical tissues and/or atrophic thymus. In addition, if a parathyroid remnant is inferiorly based, it is susceptible to devascularization by a cervical thymectomy performed in its vicinity.</p><p class="headingAnchor" id="H2325999813"><span class="h3">Resect abnormal glands with intraoperative PTH monitoring</span><span class="headingEndMark"> — </span>Despite a thorough search for the missing glands, some patients may only have two or three identifiable abnormal parathyroid glands. Intraoperative PTH monitoring may aid in the management of such patients. </p><p>Intraoperative PTH monitoring helps to guide the surgical decision-making process. In patients with primary hyperparathyroidism, established protocols (eg, the Miami protocol for primary HPT) provide assurance that all hyperfunctioning parathyroid tissue has been removed before surgery is concluded. (See  <a class="medical medical_review" href="/z/d/html/15031.html" rel="external">"Intraoperative parathyroid hormone assays", section on 'Intraoperative PTH monitoring protocols'</a>.)</p><p>However, an established intraoperative PTH monitoring protocol does not exist for ESKD-related HPT, and protocols validated in other patient populations do not apply to ESKD patients, because of delayed renal clearance of PTH [<a href="#rid33">33-36</a>]. In one study, the half-life of PTH was 6.6 minutes in ESKD patients, compared with 2.2 minutes in patients with normal renal function [<a href="#rid37">37</a>]. </p><p>Nevertheless, intraoperative PTH monitoring is used in parathyroid surgery for ESKD patients. Typically, the PTH value measured after excision is completed is compared with the baseline value. In two studies, a decline of 80 percent predicted cure [<a href="#rid37">37,38</a>]. In another study of 105 patients with stage III chronic kidney disease, stricter criteria of a &gt;50 percent decrease in PTH value <strong>and</strong> to the normal range (&lt;65 pg/mL) were associated with greater operative success (100 versus 92 percent) compared with classic criteria (a &gt;50 percent decrease in PTH value alone) [<a href="#rid39">39</a>]. Conversely, a postresection PTH level that is high or fails to decrease suggests the presence of additional abnormal glands and mandates further exploration [<a href="#rid5">5,33,34</a>]. Additionally, the laterality of a missing gland can also be determined by comparing the PTH levels of blood samples obtained from bilateral jugular veins [<a href="#rid40">40-43</a>]. </p><p class="headingAnchor" id="H2372341997"><span class="h3">Cryopreservation</span><span class="headingEndMark"> — </span>Even with careful surgery, a small percentage of patients may develop postoperative hypoparathyroidism due to either ischemic necrosis of the parathyroid remnant or early failure of an autograft. Permanent hypoparathyroidism can potentially be prevented if there is cryopreservation of parathyroid tissue at the time of the original surgery [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/15040.html" rel="external">"Parathyroid surgery for inherited syndromes", section on 'Cryopreservation'</a>.)</p><p>Our technique of preparing parathyroid tissue for cryopreservation is illustrated  (<a class="graphic graphic_picture graphicRef107531" href="/z/d/graphic/107531.html" rel="external">picture 1</a>). However, fewer than 30 percent of surgeons have access to a facility that allows cryopreservation of parathyroid tissue [<a href="#rid45">45</a>]. In the absence of cryopreservation, the surgeon must carefully calibrate the size of the parathyroid remnant or autograft to avoid permanent hypoparathyroidism. </p><p class="headingAnchor" id="H30749489"><span class="h2">Subtotal parathyroidectomy</span><span class="headingEndMark"> — </span>The basic concept of this operation is to remove nearly all abnormal parathyroid glands, leaving only a well-vascularized remnant of one gland in its anatomic location. Thus, in patients with four abnormal parathyroid glands, three are completely removed, and the fourth one is crafted into the parathyroid remnant. Near-total parathyroidectomy leaves a smaller remnant than subtotal parathyroidectomy. (See <a class="local">'Create a parathyroid remnant'</a> above.)</p><p>Subtotal parathyroidectomy is associated with a low rate of postoperative permanent hypocalcemia but a risk of potentially having to reoperate in the neck when recurrent HPT develops, reportedly in 5 to 30 percent of patients [<a href="#rid26">26,27</a>]. The risk of reoperative neck surgery can be reduced but not eliminated by performing a near-total parathyroidectomy [<a href="#rid5">5</a>]. (See <a class="local">'Patients without contraindications to reoperative neck surgery'</a> above.)</p><p class="headingAnchor" id="H2458327"><span class="h3">Creating a parathyroid remnant</span><span class="headingEndMark"> — </span>The volume of the only remaining gland is reduced to create the parathyroid remnant. Experienced surgeons can estimate the weight of a parathyroid gland in situ prior to resection [<a href="#rid26">26</a>]. The weight in milligrams is approximately the same as the volume in cubic millimeters calculated as an ellipsoid (eg, a 8 x 4 x 4 mm fragment is 64 mg)  (<a class="graphic graphic_figure graphicRef107528" href="/z/d/graphic/107528.html" rel="external">figure 2</a>) [<a href="#rid5">5,18,19</a>]. </p><p>In general, the aim is to leave approximately 50 to 100 mg of residual parathyroid tissue, equivalent to the size of two normal parathyroid glands. Remnants as small as 50 mg can be created if more extensive (eg, near-total) parathyroid excision is desired. A larger remnant (eg, &gt;100 mg) may be used to avoid postoperative hypocalcemia in patients who are noncompliant with medications or are expected to have severe postoperative bone hunger but is associated with a greater risk of disease recurrence. </p><p>Most abnormal parathyroid glands in ESKD patients weigh between 500 and 1000 mg, larger than those in patients with any other types of HPT. Thus, the traditional subtotal, or "3+1/2 gland" parathyroidectomy, which leaves 50 percent of an abnormal parathyroid gland as the remnant, may not be appropriate for ESKD patients.</p><p>A 75 percent resection of the remnant gland (near-total parathyroidectomy) has been used for ESKD patients. A more aggressive resection can be attempted when parathyroid cryopreservation is available; when cryopreservation is not available, accurate assessment of remnant size is crucial to avoid postoperative permanent hypocalcemia. </p><p>The parathyroid remnant should be created from a gland that is most readily accessible (eg, inferior glands) should a reoperation be needed. In addition, glands with well-defined vascular pedicles are preferred as remnants over those with globular or calcified features. </p><p class="headingAnchor" id="H30749496"><span class="h2">Total parathyroidectomy with heterotopic autotransplantation</span><span class="headingEndMark"> — </span>This procedure removes all cervical parathyroid glands that can be identified and simultaneously autotransplants a small portion of a gland to a new, nonanatomic site. </p><p>Although some have suggested a lower rate of recurrence after total, rather than subtotal, parathyroidectomy, the observed incidence of recurrence is still quite high (17 percent at 10 years after surgery), especially in cases of prolonged patient survival with long-term dialysis [<a href="#rid46">46</a>]. However, autograft recurrences are easier to treat than neck recurrences. (See  <a class="medical medical_review" href="/z/d/html/15040.html" rel="external">"Parathyroid surgery for inherited syndromes", section on 'Management of recurrent disease'</a>.)</p><p>The disadvantage of a total parathyroidectomy with autotransplantation is the potential for profound hypoparathyroidism and hypocalcemia if the autograft fails. Permanent hypoparathyroidism can be countered by autotransplantation of cryopreserved parathyroid tissue (where available) at a later date, although the ideal shelf life of cryopreserved tissue is limited to under two years [<a href="#rid47">47,48</a>]. (See <a class="local">'Patients with compelling reasons to avoid reoperative neck surgery'</a> above.)</p><p class="headingAnchor" id="H1996690991"><span class="h3">Creating an autograft</span><span class="headingEndMark"> — </span>The autotransplantation procedure entails mincing a portion of the excised glands into 1 to 2 mm pieces (a total of 10 to 15 pieces)  (<a class="graphic graphic_picture graphicRef107531" href="/z/d/graphic/107531.html" rel="external">picture 1</a>), which are then inserted into several muscular or subcutaneous pockets  (<a class="graphic graphic_picture graphicRef107532" href="/z/d/graphic/107532.html" rel="external">picture 2</a>). Variations of this technique have been described, including inserting each piece into an individual pocket, inserting several pieces into a pocket, or injecting a suspension of fragments into a muscle with a syringe [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H12708812"><span class="h3">Autograft sites</span><span class="headingEndMark"> — </span>A number of different sites have been utilized to host autotransplanted parathyroid tissue, including neck, chest, and forearm. The nondominant forearm is our preferred site of parathyroid autotransplantation. At each site, autografts can be placed either intramuscularly or subcutaneously. </p><p>In general, subcutaneous implantation and explantation of parathyroid autografts are simpler to perform than intramuscular procedures [<a href="#rid50">50,51</a>]. Subcutaneous implantation also permits a more radical excision than intramuscular implantation in case of a recurrent hyperparathyroidism. In one study, intramuscular autografts were more likely to require removal than subcutaneous autografts (23 versus 2 percent), but subcutaneous autografts were removed sooner after than intramuscular autografts (3.3 versus 6.6 years after implantation) [<a href="#rid52">52</a>].</p><p>Regardless of implantation sites, parathyroid fragments are sturdy and can survive in any tissue environment. Furthermore, they are small and can migrate or disperse in unpredictable directions such that resection of all foci can be challenging regardless of where the autograft is originally placed. As an example, local problems, such as parathyromatosis, have been found to complicate intramuscular implantation and subsequent resection [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H12708831"><span class="h4">Forearm</span><span class="headingEndMark"> — </span>The nondominant forearm is our preferred site of parathyroid autotransplantation  (<a class="graphic graphic_picture graphicRef107532" href="/z/d/graphic/107532.html" rel="external">picture 2</a>). The advantage of implanting parathyroid tissue into the nondominant forearm is that re-exploration, if needed for recurrent HPT, can be easily carried out under local anesthesia. Forearm autotransplantation also provides the ability to determine if an autograft is functional by comparing PTH levels of blood samples drawn from the antecubital vein of the implanted arm versus the contralateral arm.</p><p>In ESKD patients who may require parathyroid autotransplantation to the forearm, it is important to identify the nondominant arm preoperatively and to protect any present or potential future sites of dialysis access (ie, arteriovenous fistula or graft) in that forearm. (See  <a class="medical medical_review" href="/z/d/html/115151.html" rel="external">"Approach to the adult patient needing vascular access for chronic hemodialysis"</a>.)</p><p class="headingAnchor" id="H12708837"><span class="h4">Neck</span><span class="headingEndMark"> — </span>The sternocleidomastoid muscle is in the operative field of parathyroid surgery and, therefore, a convenient location for placing a parathyroid autograft. However, compared with forearm autografts, neck autografts are more difficult to retrieve at reoperations and can potentially confound imaging studies performed in search of supernumerary glands in the neck.</p><p class="headingAnchor" id="H3988420258"><span class="h4">Chest</span><span class="headingEndMark"> — </span>Some surgeons place parathyroid autografts subcutaneously in the middle to lower third of the presternal area, where they can be easily located and excised under local anesthesia in the event of a recurrence [<a href="#rid54">54</a>]. Autografts are rarely placed intramuscularly in the chest due to retrieval difficulties.</p><p class="headingAnchor" id="H30749503"><span class="h2">Total parathyroidectomy without autotransplantation</span><span class="headingEndMark"> — </span>Total parathyroidectomy without autotransplantation is the most effective surgical treatment for patients with severe refractory HPT [<a href="#rid30">30,55</a>]. It results in a faster reduction in serum calcium and PTH than subtotal parathyroidectomy [<a href="#rid56">56</a>]. It is widely practiced in countries such as Japan. </p><p>In a randomized trial of 100 patients who developed (secondary) HPT when on long-term (59±37 months) dialysis, total parathyroidectomy with or without autotransplantation resulted in comparable perioperative outcomes [<a href="#rid57">57</a>]. At three years, patients who underwent total parathyroidectomy <strong>without</strong> autotransplant had lower PTH levels (31.7±43.6 versus 98.2±156.8) and lower rates of persistent (1.9 versus 4.1 percent) or recurrent (0 versus 8.3 percent) HPT. Although parathyroid tissue was cryopreserved, no patients in either group required delayed autotransplantation for permanent hypoparathyroidism. Approximately 50 and 85 percent of patients required oral calcium and vitamin D supplementation, respectively. Approximately one-quarter of patients in each group received a renal transplant within the study follow-up period. This trial suggested that total parathyroidectomy without autotransplantation may be as safe and effective for patients with ESKD as total parathyroidectomy with autotransplantation.</p><p>In the United States, the preferred surgical treatment of HPT in patients with ESKD depends heavily on whether they are excluded from renal transplant and varies by local practices. Because total parathyroidectomy without autotransplantation has the highest risk of causing permanent hypocalcemia, it should be reserved for patients who suffer from severe complications of HPT due to lifelong dialysis (eg, bone osteodystrophy) and should be performed with parathyroid cryopreservation whenever possible [<a href="#rid47">47,48,58</a>]. (See <a class="local">'Patients excluded from renal transplant'</a> above.)</p><p class="headingAnchor" id="H17504617"><span class="h2">Reoperative parathyroid surgery</span><span class="headingEndMark"> — </span>Patients with ESKD are at a higher risk of developing multisite recurrences compared with primary HPT patients. Therefore, prior to a reoperative procedure, the surgeon should examine all available medical records, especially operative and pathology reports, to determine the most likely site(s) of recurrences. Preoperative imaging studies can help localize the recurrences as well. For patients who have previously undergone autotransplantation of parathyroid tissue, all known sites of autografts (eg, forearm) should be included in the field of view of the imaging studies. Vocal cord examination by laryngoscopy or ultrasound is also recommended prior to reoperation to exclude an occult recurrent laryngeal nerve injury from prior surgery. (See <a class="local">'Imaging for parathyroid localization'</a> below.)</p><p>At reoperation, a targeted exploration of the recurrence site(s) guided by preoperative imaging is preferred to blind bilateral neck exploration. For patients with a forearm autograft, it is not unusual to require several reoperations to completely remove autografts from the forearm because of regrowth [<a href="#rid46">46</a>]. Thus, if appropriate, a surgeon may choose to excise all visible autograft tissue without leaving a new, smaller autograft behind.</p><p>The principles of reoperative parathyroidectomy for ESKD patients are the same as those for primary HPT patients and are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2069.html" rel="external">"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism", section on 'Reoperation for recurrent or persistent hyperparathyroidism'</a>.)</p><p class="headingAnchor" id="H10683577"><span class="h1">PERIOPERATIVE CONSIDERATIONS</span></p><p class="headingAnchor" id="H1305122671"><span class="h2">Preoperative risk assessment</span><span class="headingEndMark"> — </span>A thorough preoperative risk assessment of end-stage kidney disease (ESKD) patients is important for the selection of appropriate surgical candidates, as patients who have ESKD may have comorbidities that preclude safe surgery. </p><p>ESKD patients often have chronic medical conditions such as coronary artery disease, heart failure, myocardial infarction, hypertension, stroke, anemia, uremic coagulopathy, pulmonary disease, and general debility [<a href="#rid59">59-61</a>]. In addition, patients with calciphylaxis have unique complications such as peripheral vascular disease and wound sepsis [<a href="#rid28">28,29,62</a>] (see  <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">"Calciphylaxis (calcific uremic arteriolopathy)"</a>). Although patients are generally healthier after a renal transplant, their immune system is medically suppressed, which increases their risk of developing postoperative complications. </p><p>The preoperative medical evaluation of patients with ESKD is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">"Medical management of the dialysis patient undergoing surgery", section on 'Preoperative evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/6616.html" rel="external">"Evaluation of cardiac risk prior to noncardiac surgery"</a>.)</p><p class="headingAnchor" id="H3459049584"><span class="h2">Patient counseling</span><span class="headingEndMark"> — </span>Prior to parathyroid surgery, patients need to be counseled about the potential outcomes in order for them to formulate realistic expectations. Specifically, patients should be advised that they may face a lengthy recovery, during which time they could develop hungry bone syndrome, and that they are at risk of developing recurrent hyperparathyroidism (HPT) as long as they remain on dialysis.</p><p class="headingAnchor" id="H4035059019"><span class="h3">Hungry bone syndrome</span><span class="headingEndMark"> — </span>Hungry bone syndrome is a condition of hyperdynamic calcium reabsorption into bones following parathyroidectomy, leading to protracted and symptomatic hypocalcemia. In one study, severe postoperative hypocalcemia requiring intravenous calcium repletion occurred in 97 percent of ESKD patients with HPT but only 2 percent of those with primary HPT [<a href="#rid63">63</a>]. Prevention and treatment of hungry bone syndrome are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2070.html" rel="external">"Hungry bone syndrome following parathyroidectomy in patients with end-stage kidney disease"</a>.)</p><p class="headingAnchor" id="H574631260"><span class="h3">Recurrent hyperparathyroidism</span><span class="headingEndMark"> — </span>The risk of developing recurrent HPT in patients who remain on dialysis after a successful parathyroidectomy can be as high as 80 percent [<a href="#rid22">22,64-66</a>]. Thus, some ESKD patients need repeated parathyroid surgeries for HPT. Patients need to be counseled about the natural history of their disease prior to surgery in order for them to set realistic expectations about the outcomes. (See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Abnormalities of parathyroid hormone, calcium, phosphorus, fibroblast growth factor 23, and vitamin D metabolism'</a>.)</p><p class="headingAnchor" id="H1210371930"><span class="h3">Expected length of recovery</span><span class="headingEndMark"> — </span>Following parathyroid surgery in ESKD patients, it may take several months to achieve an optimal calcium, parathyroid hormone (PTH), and vitamin D balance, an even longer time to get symptomatic relief from HPT-related sequelae, and several years to restore a normal bone density [<a href="#rid1">1,5</a>]. During that time, patients should be assessed at regular intervals to document progress, which can alleviate their anxiety.</p><p class="headingAnchor" id="H1290321033"><span class="h2">Imaging for parathyroid localization</span><span class="headingEndMark"> — </span>For patients undergoing parathyroid surgery for HPT, including those with ESKD, cervical ultrasound can be performed to assist with operative planning [<a href="#rid67">67,68</a>]. Preoperative ultrasound examination improves the efficiency of parathyroid surgery by facilitating surgical exposure, guiding the sequence of exploration, and optimizing the choice of a parathyroid remnant. Cervical ultrasound can also identify abnormalities in the thyroid gland that may require further evaluation and/or concomitant surgical management during the parathyroidectomy [<a href="#rid69">69-80</a>]. (See <a class="local">'Patients with thyroid cancer'</a> below.)</p><p>Other modalities of parathyroid imaging have limited accuracies in ESKD patients and are <strong>not</strong> routinely required [<a href="#rid81">81-83</a>]. Patients undergoing targeted parathyroidectomy for either tertiary HPT (post-renal-transplant HPT) or recurrent HPT, however, may require further studies to localize the abnormal glands. (See  <a class="medical medical_review" href="/z/d/html/2069.html" rel="external">"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism", section on 'Role of preoperative localization'</a>.)</p><p class="headingAnchor" id="H1360625328"><span class="h2">Coordination of care with nephrologists and dialysis centers</span><span class="headingEndMark"> — </span>For patients who are on scheduled dialysis, parathyroid surgery needs to be planned according to their dialysis schedule to avoid unnecessary delay caused by conditions such as hyperkalemia. After surgery, the patient's nephrologist can assist in the administration of calcium and vitamin D. The involvement of a nephrologist has been shown to reduce the length of hospital stay after parathyroid surgery [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H463007894"><span class="h2">Anesthesia</span><span class="headingEndMark"> — </span>General anesthesia is required for most patients undergoing parathyroidectomy with bilateral neck exploration [<a href="#rid45">45</a>]. Other options, including local anesthesia, have been described but are rarely used [<a href="#rid45">45,85</a>]. Patient monitoring follows established routine practices. (See  <a class="medical medical_review" href="/z/d/html/94254.html" rel="external">"Anesthesia for dialysis patients"</a>.)</p><p class="headingAnchor" id="H4192012425"><span class="h2">Equipment</span><span class="headingEndMark"> — </span>Instruments required to perform parathyroid surgery vary depending upon the surgeon and technique [<a href="#rid86">86-88</a>]. A basic setup is shown in the picture  (<a class="graphic graphic_picture graphicRef107533" href="/z/d/graphic/107533.html" rel="external">picture 3</a>). </p><p class="headingAnchor" id="H3944928724"><span class="h2">Patient positioning</span><span class="headingEndMark"> — </span>Patients undergoing parathyroid surgery are placed in the supine position with the neck gently hyperextended. Potential sites of autotransplantation should be exposed and prepared [<a href="#rid1">1,5,49,89,90</a>]. (See <a class="local">'Autograft sites'</a> above and  <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">"Parathyroid exploration for primary hyperparathyroidism", section on 'Positioning'</a>.)</p><p class="headingAnchor" id="H1580858835"><span class="h2">Patients with thyroid cancer</span><span class="headingEndMark"> — </span>ESKD patients who have newly diagnosed thyroid cancer by preoperative neck ultrasound or intraoperatively during parathyroid surgery may require concomitant thyroid surgery [<a href="#rid91">91</a>]. Patients with clinically significant thyroid cancer are excluded from renal transplantation for at least two years after their treatment. Thus, these patients should be comanaged by a multidisciplinary team consisting of nephrologists, surgeons, and endocrinologists to address unique issues such as the dosing of radioactive iodine in patients with renal failure. (See  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment", section on 'Radioiodine dose (activity)'</a>.)</p><p>Post-renal-transplant patients with thyroid cancer have similar prognosis compared with the general population. (See  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H30749575"><span class="h1">POSTOPERATIVE CARE</span><span class="headingEndMark"> — </span>General postparathyroidectomy care is the same for end-stage kidney disease (ESKD) patients as for those with primary hyperparathyroidism (HPT) and is detailed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">"Parathyroid exploration for primary hyperparathyroidism", section on 'Postoperative care'</a>.)</p><p>Compared with patients with primary HPT, ESKD patients are more likely to develop transient hypocalcemia after parathyroid surgery due to hungry bone syndrome. A retrospective study of 2756 parathyroidectomies performed in patients with chronic kidney disease showed an unplanned readmission rate of 17 percent, which is nearly five times that of the general population; almost one-half of the admissions were for hypocalcemia/hungry bone syndrome [<a href="#rid92">92</a>]. Furthermore, parathyroid surgery performed for secondary hyperparathyroidism was more than two times as likely to require readmissions as surgery performed for primary hyperparathyroidism. </p><p>Thus, many institutions have protocols in place to administer preoperative <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> as well as postoperative intravenous <a class="drug drug_general" data-topicid="9190" href="/z/d/drug information/9190.html" rel="external">calcium gluconate</a>, along with oral calcium, magnesium, and vitamin D (calcitriol) when necessary. Once patients are weaned off intravenous calcium, they are discharged home on an aggressive regimen of oral calcium and vitamin D replacement, with which they must be compliant for best results. Additional intravenous calcium replacement may be required during dialysis or readmission for patients who develop severe symptoms of hypocalcemia. The treatment of symptomatic hypocalcemia is also discussed in another topic. (See  <a class="medical medical_review" href="/z/d/html/826.html" rel="external">"Treatment of hypocalcemia"</a>.) </p><p>Wound care for both the cervical and autograft site incisions is standard and basic. Patients typically do not require pain medications stronger than <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>. Patients may resume dialysis after surgery, although some surgeons prefer to omit heparin during the first few sessions of dialysis after surgery to minimize the risk of neck hematoma.</p><p class="headingAnchor" id="H30749582"><span class="h1">FOLLOW-UP CARE</span><span class="headingEndMark"> — </span>Laboratory values obtained over time indicate the adequacy of vitamin D repletion and the degree of long-term cure. At two weeks after surgery, the following are typically obtained as a baseline laboratory profile:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum and ionized calcium</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Magnesium</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intact parathyroid hormone (PTH) </p><p></p><p>Then, at three and six months, the levels of 25-hydroxyvitamin D and 1,25-hydroxyvitamin D are also measured. Dialysis and transplant services may obtain laboratory studies more frequently. </p><p>The time it takes for end-stage kidney disease (ESKD) patients to achieve new homeostasis of calcium, vitamin D, and PTH can vary significantly. Thus, ESKD patients require long-term follow-up after surgery for possible endocrinopathies such as hyper-/hypocalcemia and hyper-/hypoparathyroidism. Although laboratory values at six months after surgery have traditionally been used to predict durable cure in patients with primary hyperparathyroidism, no similar consensus exists for ESKD patients. (See  <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">"Parathyroid exploration for primary hyperparathyroidism", section on 'Postoperative care'</a>.)</p><p class="headingAnchor" id="H30749589"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Despite a higher preoperative risk due to tissue fragility and uremic coagulopathy, parathyroid surgery for end-stage kidney disease (ESKD) patients is safe and has a similar complication rate when compared with surgery for primary HPT patients [<a href="#rid5">5,23</a>]. The main technical complications include: </p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding (including hematoma)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Voice hoarseness or change (due to recurrent laryngeal nerve injury)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypoparathyroidism</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent/recurrent hyperparathyroidism </p><p></p><p>Specific complications of parathyroid surgery and their treatment are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">"Parathyroid exploration for primary hyperparathyroidism", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H30749596"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>The immediate goal of parathyroid surgery is to reduce the parathyroid hormone (PTH) level; the ultimate goal is to achieve long-lasting symptom relief and end organ improvement. It is not clear, however, what percentage of PTH needs to be reduced before the ultimate goal can be achieved. Patient outcomes also depend heavily upon the progression of their underlying renal disease. </p><p>Several studies have shown that parathyroid surgery halted progression or reversed bone loss from end-stage kidney disease (ESKD) or from steroid use (in renal transplant recipients) [<a href="#rid5">5,22</a>]. Other patient-specific outcomes (eg, hypercalcemia, hyperphosphatemia, bone pain, pruritus, and myopathy) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis", section on 'Potential indications for parathyroidectomy'</a>.)</p><p>However, in hemodialysis patients with secondary hyperparathyroidism, surgery significantly improves quality of life, regardless of whether a subtotal parathyroidectomy or a total parathyroidectomy with autotransplantation is performed [<a href="#rid93">93</a>]. </p><p class="headingAnchor" id="H3635579571"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114502.html" rel="external">"Society guideline links: Parathyroid surgery"</a>.)</p><p class="headingAnchor" id="H30749603"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Parathyroid surgery in patients with end-stage kidney disease (ESKD) is an effective therapy for normalization or stabilization of calcium and parathyroid hormone (PTH) metabolism and for improving renal osteodystrophy. ESKD patients who have markedly elevated, medical-therapy-refractory PTH levels and related signs and symptoms should be referred for parathyroidectomy. (See <a class="local">'Introduction'</a> above and <a class="local">'Indications'</a> above and  <a class="medical medical_review" href="/z/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients with ESKD have multigland hyperplasia and, for initial parathyroid surgery, therefore, require subtotal or total parathyroidectomy after identifying all four glands, rather than targeted parathyroidectomy. (See <a class="local">'For the initial parathyroid surgery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For ESKD patients with an existing or planned renal transplant, we perform either a subtotal parathyroidectomy or a total parathyroidectomy with autotransplantation. Total parathyroidectomy without autotransplantation should be avoided in this setting because it is associated with the highest risk of postoperative permanent hypocalcemia, which is difficult to treat once the patient is no longer dialysis dependent after renal transplantation. (See <a class="local">'Patients with existing or planned renal transplant'</a> above.)</p><p></p><p class="bulletIndent2">During a subtotal parathyroidectomy, a parathyroid remnant equivalent to the size of two normal parathyroid glands (approximately 50 to 100 mg) should be created from a gland that is most accessible and has the best possible blood supply before the other glands are resected. (See <a class="local">'Subtotal parathyroidectomy'</a> above.)</p><p></p><p class="bulletIndent2">During a total parathyroidectomy with autotransplantation, the autograft can be placed subcutaneously or intramuscularly in the neck (sternocleidomastoid muscle), chest, or nondominant forearm by surgeon preference. (See <a class="local">'Total parathyroidectomy with heterotopic autotransplantation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients excluded from renal transplant, we suggest performing a total parathyroidectomy without autotransplantation rather than the other surgical options (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Total parathyroidectomy without autotransplantation is the most effective surgical treatment for severe refractory hyperparathyroidism, which commonly occurs in this group of patients. (See <a class="local">'Patients excluded from renal transplant'</a> above and <a class="local">'Total parathyroidectomy without autotransplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For ESKD patients with recurrent hyperparathyroidism, we perform a targeted exploration of recurrent sites (including autograft sites), guided by preoperative imaging studies and intraoperative PTH assays, rather than blind bilateral neck exploration. (See <a class="local">'Reoperative parathyroid surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compared with patients with primary hyperparathyroidism, ESKD patients are more likely to develop transient hypocalcemia after parathyroid surgery due to hungry bone syndrome. Thus, many institutions have protocols in place to administer intravenous <a class="drug drug_general" data-topicid="9190" href="/z/d/drug information/9190.html" rel="external">calcium gluconate</a> along with oral calcium, magnesium, and vitamin D (<a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a>) when necessary. Patients are discharged home on an aggressive regimen of oral calcium and vitamin D replacement. </p><p></p><p class="headingAnchor" id="H3538067361"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Dr. Benjamin O Lawson, who contributed significantly to this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sharma J, Weber C. Surgical management of hyperparathyroidism in renal failure. Clin Rev Bone Miner Metab 2007; 5:103.</a></li><li><a class="nounderline abstract_t">Rayes N, Seehofer D, Schindler R, et al. Long-term results of subtotal vs total parathyroidectomy without autotransplantation in kidney transplant recipients. Arch Surg 2008; 143:756.</a></li><li><a class="nounderline abstract_t">Collaud S, Staub-Zähner T, Trombetti A, et al. Increase in bone mineral density after successful parathyroidectomy for tertiary hyperparathyroidism after renal transplantation. World J Surg 2008; 32:1795.</a></li><li><a class="nounderline abstract_t">Mazzaferro S, Pasquali M, Farcomeni A, et al. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Nephrol Dial Transplant 2008; 23:2319.</a></li><li><a class="nounderline abstract_t">Milas M, Weber CJ. Near-total parathyroidectomy is beneficial for patients with secondary and tertiary hyperparathyroidism. Surgery 2004; 136:1252.</a></li><li><a class="nounderline abstract_t">Foley RN, Li S, Liu J, et al. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 2005; 16:210.</a></li><li><a class="nounderline abstract_t">Elder GJ. Parathyroidectomy in the calcimimetic era. Nephrology (Carlton) 2005; 10:511.</a></li><li><a class="nounderline abstract_t">Torregrosa JV, Bergua C, Martinez de Osaba MJ, et al. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis. Transplant Proc 2009; 41:2396.</a></li><li><a class="nounderline abstract_t">López V, Toledo R, Sola E, et al. Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism. Transplant Proc 2009; 41:2394.</a></li><li><a class="nounderline abstract_t">Tominaga Y, Matsuoka S, Uno N, Sato T. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics. Ther Apher Dial 2008; 12 Suppl 1:S21.</a></li><li><a class="nounderline abstract_t">Yokoyama K. Clinical issues regarding cinacalcet hydrochloride in Japan. Ther Apher Dial 2009; 13 Suppl 1:S12.</a></li><li><a class="nounderline abstract_t">Bergua C, Torregrosa JV, Cofán F, Oppenheimer F. Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. Transplant Proc 2007; 39:2254.</a></li><li><a class="nounderline abstract_t">Narayan R, Perkins RM, Berbano EP, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007; 49:801.</a></li><li><a class="nounderline abstract_t">El-Amm JM, Doshi MD, Singh A, et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007; 83:546.</a></li><li><a class="nounderline abstract_t">Wüthrich RP, Martin D, Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 2007; 37:915.</a></li><li class="breakAll">Ritter H, Milas M. Parathyroidectomy: Bilateral neck exploration. In: Operative Techniques in Otolaryngology, Terris D (Ed), Elsevier, St. Louis 2009. p.44.</li><li><a class="nounderline abstract_t">Pattou FN, Pellissier LC, Noël C, et al. Supernumerary parathyroid glands: frequency and surgical significance in treatment of renal hyperparathyroidism. World J Surg 2000; 24:1330.</a></li><li><a class="nounderline abstract_t">Tominaga Y, Tanaka Y, Sato K, et al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997; 13:78.</a></li><li><a class="nounderline abstract_t">Matsuoka S, Tominaga Y, Sato T, et al. Relationship between the dimension of parathyroid glands estimated by ultrasonography and the hyperplastic pattern in patients with renal hyperparathyroidism. Ther Apher Dial 2008; 12:391.</a></li><li><a class="nounderline abstract_t">Kebebew E, Duh QY, Clark OH. Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy. Arch Surg 2004; 139:974.</a></li><li><a class="nounderline abstract_t">Nichol PF, Starling JR, Mack E, et al. Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma. Ann Surg 2002; 235:673.</a></li><li><a class="nounderline abstract_t">Pitt SC, Sippel RS, Chen H. Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin North Am 2009; 89:1227.</a></li><li><a class="nounderline abstract_t">Shen WT, Kebebew E, Suh I, et al. Two hundred and two consecutive operations for secondary hyperparathyroidism: has medical management changed the profiles of patients requiring parathyroidectomy? Surgery 2009; 146:296.</a></li><li><a class="nounderline abstract_t">Schlosser K, Endres N, Celik I, et al. Surgical treatment of tertiary hyperparathyroidism: the choice of procedure matters! World J Surg 2007; 31:1947.</a></li><li><a class="nounderline abstract_t">Choi HR, Aboueisha MA, Attia AS, et al. Outcomes of Subtotal Parathyroidectomy Versus Total Parathyroidectomy With Autotransplantation for Tertiary Hyperparathyroidism: Multi-institutional Study. Ann Surg 2021; 274:674.</a></li><li><a class="nounderline abstract_t">Rothmund M, Wagner PK, Schark C. Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial. World J Surg 1991; 15:745.</a></li><li><a class="nounderline abstract_t">Nicholson ML, Veitch PS, Feehally J. Parathyroidectomy in chronic renal failure: comparison of three operative strategies. J R Coll Surg Edinb 1996; 41:382.</a></li><li><a class="nounderline abstract_t">Lal G, Nowell AG, Liao J, et al. Determinants of survival in patients with calciphylaxis: a multivariate analysis. Surgery 2009; 146:1028.</a></li><li><a class="nounderline abstract_t">Milas M, Bush RL, Lin P, et al. Calciphylaxis and nonhealing wounds: the role of the vascular surgeon in a multidisciplinary treatment. J Vasc Surg 2003; 37:501.</a></li><li><a class="nounderline abstract_t">de Francisco AL, Fresnedo GF, Rodrigo E, et al. Parathyroidectomy in dialysis patients. Kidney Int Suppl 2002; :161.</a></li><li><a class="nounderline abstract_t">Stephen AE, Milas M, Garner CN, et al. Use of surgeon-performed office ultrasound and parathyroid fine needle aspiration for complex parathyroid localization. Surgery 2005; 138:1143.</a></li><li><a class="nounderline abstract_t">Boltz MM, Zhang N, Zhao C, et al. Value of Prophylactic Cervical Thymectomy in Parathyroid Hyperplasia. Ann Surg Oncol 2015; 22 Suppl 3:S662.</a></li><li><a class="nounderline abstract_t">Ikeda Y, Kurihara H, Morita N, et al. The role of quick bio-intact PTH(1-84) assay during parathyroidectomy for secondary hyperparathyroidism. J Surg Res 2007; 141:306.</a></li><li><a class="nounderline abstract_t">Triponez F, Dosseh D, Hazzan M, et al. Accuracy of intra-operative PTH measurement during subtotal parathyroidectomy for tertiary hyperparathyroidism after renal transplantation. Langenbecks Arch Surg 2006; 391:561.</a></li><li><a class="nounderline abstract_t">Seehofer D, Rayes N, Klupp J, et al. Predictive value of intact parathyroid hormone measurement during surgery for renal hyperparathyroidism. Langenbecks Arch Surg 2005; 390:222.</a></li><li><a class="nounderline abstract_t">Komaba H, Goto S, Fukagawa M. Critical issues of PTH assays in CKD. Bone 2009; 44:666.</a></li><li><a class="nounderline abstract_t">Ohe MN, Santos RO, Kunii IS, et al. Intraoperative PTH cutoff definition to predict successful parathyroidectomy in secondary and tertiary hyperparathyroidism. Braz J Otorhinolaryngol 2013; 79:494.</a></li><li><a class="nounderline abstract_t">Silveira AA, Brescia MDG, do Nascimento CP Jr, et al. Critical analysis of the intraoperative parathyroid hormone decrease during parathyroidectomy for secondary and tertiary hyperparathyroidism. Surgery 2020; 168:1079.</a></li><li><a class="nounderline abstract_t">Liu SN, Yusufali AH, Mao ML, et al. Stricter ioPTH criterion for successful parathyroidectomy in stage III CKD patients with primary hyperparathyroidism. Surgery 2018; 164:1306.</a></li><li><a class="nounderline abstract_t">Ito F, Sippel R, Lederman J, Chen H. The utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing. Ann Surg 2007; 245:959.</a></li><li><a class="nounderline abstract_t">Barczynski M, Konturek A, Hubalewska-Dydejczyk A, et al. Utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing in guiding patients with a negative sestamibi scan for minimally invasive parathyroidectomy--a randomized controlled trial. Langenbecks Arch Surg 2009; 394:827.</a></li><li><a class="nounderline abstract_t">Bergenfelz A, Algotsson L, Roth B, et al. Side localization of parathyroid adenomas by simplified intraoperative venous sampling for parathyroid hormone. World J Surg 1996; 20:358.</a></li><li><a class="nounderline abstract_t">Alvarado R, Meyer-Rochow G, Sywak M, et al. Bilateral internal jugular venous sampling for parathyroid hormone determination in patients with nonlocalizing primary hyperparathyroidism. World J Surg 2010; 34:1299.</a></li><li><a class="nounderline abstract_t">Agarwal A, Waghray A, Gupta S, et al. Cryopreservation of parathyroid tissue: an illustrated technique using the cleveland clinic protocol. J Am Coll Surg 2013; 216:e1.</a></li><li><a class="nounderline abstract_t">Greene AB, Butler RS, McIntyre S, et al. National trends in parathyroid surgery from 1998 to 2008: a decade of change. J Am Coll Surg 2009; 209:332.</a></li><li><a class="nounderline abstract_t">Tominaga Y, Matsuoka S, Uno N, et al. Removal of autografted parathyroid tissue for recurrent renal hyperparathyroidism in hemodialysis patients. World J Surg 2010; 34:1312.</a></li><li><a class="nounderline abstract_t">de Menezes Montenegro FL, Custódio MR, Arap SS, et al. Successful implant of long-term cryopreserved parathyroid glands after total parathyroidectomy. Head Neck 2007; 29:296.</a></li><li><a class="nounderline abstract_t">Guerrero MA, Evans DB, Lee JE, et al. Viability of cryopreserved parathyroid tissue: when is continued storage versus disposal indicated? World J Surg 2008; 32:836.</a></li><li><a class="nounderline abstract_t">Echenique-Elizondo M, Amondarain JA, Vidaur F, et al. Parathyroid subcutaneous pre-sternal transplantation after parathyroidectomy for renal hyperparathyroidism. Long-term graft function. World J Surg 2007; 31:1403.</a></li><li><a class="nounderline abstract_t">Chou FF, Chan HM, Huang TJ, et al. Autotransplantation of parathyroid glands into subcutaneous forearm tissue for renal hyperparathyroidism. Surgery 1998; 124:1.</a></li><li><a class="nounderline abstract_t">Monchik JM, Bendinelli C, Passero MA Jr, Roggin KK. Subcutaneous forearm transplantation of autologous parathyroid tissue in patients with renal hyperparathyroidism. Surgery 1999; 126:1152.</a></li><li><a class="nounderline abstract_t">Hsu YC, Hung CJ. Intramuscular and subcutaneous forearm parathyroid autograft hyperplasia in renal dialysis patients: A retrospective cohort study. Surgery 2015; 158:1331.</a></li><li><a class="nounderline abstract_t">Melck AL, Carty SE, Seethala RR, et al. Recurrent hyperparathyroidism and forearm parathyromatosis after total parathyroidectomy. Surgery 2010; 148:867.</a></li><li><a class="nounderline abstract_t">Echenique-Elizondo M, Díaz-Aguirregoitia FJ, Amondarain JA, Vidaur F. Parathyroid graft function after presternal subcutaneous autotransplantation for renal hyperparathyroidism. Arch Surg 2006; 141:33.</a></li><li><a class="nounderline abstract_t">Ockert S, Willeke F, Richter A, et al. Total parathyroidectomy without autotransplantation as a standard procedure in the treatment of secondary hyperparathyroidism. Langenbecks Arch Surg 2002; 387:204.</a></li><li><a class="nounderline abstract_t">Lumachi F, Basso SM. Pathophysiology and treatment of nonfamilial hyperparathyroidism. Recent Pat CNS Drug Discov 2014; 9:164.</a></li><li><a class="nounderline abstract_t">Schlosser K, Bartsch DK, Diener MK, et al. Total Parathyroidectomy With Routine Thymectomy and Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism: Results of a Nonconfirmatory Multicenter Prospective Randomized Controlled Pilot Trial. Ann Surg 2016; 264:745.</a></li><li><a class="nounderline abstract_t">Caccitolo JA, Farley DR, van Heerden JA, et al. The current role of parathyroid cryopreservation and autotransplantation in parathyroid surgery: an institutional experience. Surgery 1997; 122:1062.</a></li><li><a class="nounderline abstract_t">Obrador GT, Pereira BJ, Kausz AT. Chronic kidney disease in the United States: an underrecognized problem. Semin Nephrol 2002; 22:441.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors--United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007; 56:161.</a></li><li><a class="nounderline abstract_t">Clark LE, Khan I. Outcomes in CKD: what we know and what we need to know. Nephron Clin Pract 2010; 114:c95.</a></li><li><a class="nounderline abstract_t">Yeh SM, Hwang SJ, Chen HC. Treatment of severe metastatic calcification in hemodialysis patients. Hemodial Int 2009; 13:163.</a></li><li><a class="nounderline abstract_t">Mittendorf EA, Merlino JI, McHenry CR. Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg 2004; 70:114.</a></li><li><a class="nounderline abstract_t">Stracke S, Keller F, Steinbach G, et al. Long-term outcome after total parathyroidectomy for the management of secondary hyperparathyroidism. Nephron Clin Pract 2009; 111:c102.</a></li><li><a class="nounderline abstract_t">Low TH, Clark J, Gao K, et al. Outcome of parathyroidectomy for patients with renal disease and hyperparathyroidism: predictors for recurrent hyperparathyroidism. ANZ J Surg 2009; 79:378.</a></li><li><a class="nounderline abstract_t">Triponez F, Kebebew E, Dosseh D, et al. Less-than-subtotal parathyroidectomy increases the risk of persistent/recurrent hyperparathyroidism after parathyroidectomy in tertiary hyperparathyroidism after renal transplantation. Surgery 2006; 140:990.</a></li><li><a class="nounderline abstract_t">Wilhelm SM, Lee JA, Ruan DE, et al. The American Association of Endocrine Surgeons (AAES) guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 2016.</a></li><li><a class="nounderline abstract_t">Udelsman R, Åkerström G, Biagini C, et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3595.</a></li><li><a class="nounderline abstract_t">Morita SY, Somervell H, Umbricht CB, et al. Evaluation for concomitant thyroid nodules and primary hyperparathyroidism in patients undergoing parathyroidectomy or thyroidectomy. Surgery 2008; 144:862.</a></li><li><a class="nounderline abstract_t">Adler JT, Chen H, Schaefer S, Sippel RS. Does routine use of ultrasound result in additional thyroid procedures in patients with primary hyperparathyroidism? J Am Coll Surg 2010; 211:536.</a></li><li><a class="nounderline abstract_t">Bentrem DJ, Angelos P, Talamonti MS, Nayar R. Is preoperative investigation of the thyroid justified in patients undergoing parathyroidectomy for hyperparathyroidism? Thyroid 2002; 12:1109.</a></li><li><a class="nounderline abstract_t">Beus KS, Stack BC Jr. Synchronous thyroid pathology in patients presenting with primary hyperparathyroidism. Am J Otolaryngol 2004; 25:308.</a></li><li><a class="nounderline abstract_t">Erbil Y, Salmaslioğlu A, Kabul E, et al. Use of preoperative parathyroid fine-needle aspiration and parathormone assay in the primary hyperparathyroidism with concomitant thyroid nodules. Am J Surg 2007; 193:665.</a></li><li><a class="nounderline abstract_t">Krause UC, Friedrich JH, Olbricht T, Metz K. Association of primary hyperparathyroidism and non-medullary thyroid cancer. Eur J Surg 1996; 162:685.</a></li><li><a class="nounderline abstract_t">Masatsugu T, Yamashita H, Noguchi S, et al. Thyroid evaluation in patients with primary hyperparathyroidism. Endocr J 2005; 52:177.</a></li><li><a class="nounderline abstract_t">Milas M, Mensah A, Alghoul M, et al. The impact of office neck ultrasonography on reducing unnecessary thyroid surgery in patients undergoing parathyroidectomy. Thyroid 2005; 15:1055.</a></li><li><a class="nounderline abstract_t">Ogawa T, Kammori M, Tsuji E, et al. Preoperative evaluation of thyroid pathology in patients with primary hyperparathyroidism. Thyroid 2007; 17:59.</a></li><li><a class="nounderline abstract_t">Ryan S, Courtney D, Timon C. Co-existent thyroid disease in patients treated for primary hyperparathyroidism: implications for clinical management. Eur Arch Otorhinolaryngol 2015; 272:419.</a></li><li><a class="nounderline abstract_t">Sidhu S, Campbell P. Thyroid pathology associated with primary hyperparathyroidism. Aust N Z J Surg 2000; 70:285.</a></li><li><a class="nounderline abstract_t">Wagner B, Begic-Karup S, Raber W, et al. Prevalence of primary hyperparathyroidism in 13387 patients with thyroid diseases, newly diagnosed by screening of serum calcium. Exp Clin Endocrinol Diabetes 1999; 107:457.</a></li><li><a class="nounderline abstract_t">Gasparri G, Camandona M, Bertoldo U, et al. The usefulness of preoperative dual-phase 99mTc MIBI-scintigraphy and IO-PTH assay in the treatment of secondary and tertiary hyperparathyroidism. Ann Surg 2009; 250:868.</a></li><li><a class="nounderline abstract_t">de la Rosa A, Jimeno J, Membrilla E, et al. Usefulness of preoperative Tc-mibi parathyroid scintigraphy in secondary hyperparathyroidism. Langenbecks Arch Surg 2008; 393:21.</a></li><li><a class="nounderline abstract_t">Pham TH, Sterioff S, Mullan BP, et al. Sensitivity and utility of parathyroid scintigraphy in patients with primary versus secondary and tertiary hyperparathyroidism. World J Surg 2006; 30:327.</a></li><li><a class="nounderline abstract_t">Cheng SP, Liu CL, Chen HH, et al. Prolonged hospital stay after parathyroidectomy for secondary hyperparathyroidism. World J Surg 2009; 33:72.</a></li><li><a class="nounderline abstract_t">Cheong YT, Taib NA, Normayah K, Hisham AN. Total parathyroidectomy under local anaesthesia for renal hyperparathyroidism. Asian J Surg 2009; 32:51.</a></li><li><a class="nounderline abstract_t">Sun Y, Cai H, Bai J, et al. Endoscopic total parathyroidectomy and partial parathyroid tissue autotransplantation for patients with secondary hyperparathyroidism: a new surgical approach. World J Surg 2009; 33:1674.</a></li><li><a class="nounderline abstract_t">Barbaros U, Erbil Y, Yildirim A, et al. Minimally invasive video-assisted subtotal parathyroidectomy with thymectomy for secondary hyperparathyroidism. Langenbecks Arch Surg 2009; 394:451.</a></li><li><a class="nounderline abstract_t">Ismail M, Maza S, Swierzy M, et al. Resection of ectopic mediastinal parathyroid glands with the da Vinci robotic system. Br J Surg 2010; 97:337.</a></li><li><a class="nounderline abstract_t">Tominaga Y, Matsuoka S, Sato T. Surgical indications and procedures of parathyroidectomy in patients with chronic kidney disease. Ther Apher Dial 2005; 9:44.</a></li><li><a class="nounderline abstract_t">Lorenz K, Ukkat J, Sekulla C, et al. Total parathyroidectomy without autotransplantation for renal hyperparathyroidism: experience with a qPTH-controlled protocol. World J Surg 2006; 30:743.</a></li><li><a class="nounderline abstract_t">Veroux M, Giuffrida G, Gagliano M, et al. Evaluation of thyroid disease in kidney transplantation candidates: management and follow-up. Transplant Proc 2009; 41:1142.</a></li><li><a class="nounderline abstract_t">Ferrandino R, Roof S, Ma Y, et al. Unplanned 30-Day Readmissions after Parathyroidectomy in Patients with Chronic Kidney Disease: A Nationwide Analysis. Otolaryngol Head Neck Surg 2017; 157:955.</a></li><li><a class="nounderline abstract_t">Filho WA, van der Plas WY, Brescia MDG, et al. Quality of life after surgery in secondary hyperparathyroidism, comparing subtotal parathyroidectomy with total parathyroidectomy with immediate parathyroid autograft: Prospective randomized trial. Surgery 2018; 164:978.</a></li></ol></div><div id="topicVersionRevision">Topic 15041 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Surgical management of hyperparathyroidism in renal failure</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18711035" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Long-term results of subtotal vs total parathyroidectomy without autotransplantation in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18311499" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Increase in bone mineral density after successful parathyroidectomy for tertiary hyperparathyroidism after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18281320" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15657584" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Near-total parathyroidectomy is beneficial for patients with secondary and tertiary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15563573" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16221104" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Parathyroidectomy in the calcimimetic era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19715931" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19715930" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19032523" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19765252" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical issues regarding cinacalcet hydrochloride in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17889155" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17533023" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353771" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18036025" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The role of calcimimetics in the treatment of hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18036025" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The role of calcimimetics in the treatment of hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11038202" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Supernumerary parathyroid glands: frequency and surgical significance in treatment of renal hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9088063" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18937723" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Relationship between the dimension of parathyroid glands estimated by ultrasonography and the hyperplastic pattern in patients with renal hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15381615" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981213" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19836494" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Secondary and tertiary hyperparathyroidism, state of the art surgical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628088" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Two hundred and two consecutive operations for secondary hyperparathyroidism: has medical management changed the profiles of patients requiring parathyroidectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17665243" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Surgical treatment of tertiary hyperparathyroidism: the choice of procedure matters!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34506323" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Outcomes of Subtotal Parathyroidectomy Versus Total Parathyroidectomy With Autotransplantation for Tertiary Hyperparathyroidism: Multi-institutional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1767541" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8997024" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Parathyroidectomy in chronic renal failure: comparison of three operative strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19958929" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Determinants of survival in patients with calciphylaxis: a multivariate analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12618682" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Calciphylaxis and nonhealing wounds: the role of the vascular surgeon in a multidisciplinary treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11982831" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Parathyroidectomy in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16360402" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Use of surgeon-performed office ultrasound and parathyroid fine needle aspiration for complex parathyroid localization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26353764" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Value of Prophylactic Cervical Thymectomy in Parathyroid Hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17418873" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The role of quick bio-intact PTH(1-84) assay during parathyroidectomy for secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16909294" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Accuracy of intra-operative PTH measurement during subtotal parathyroidectomy for tertiary hyperparathyroidism after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15726399" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Predictive value of intact parathyroid hormone measurement during surgery for renal hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19159701" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Critical issues of PTH assays in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23929152" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intraoperative PTH cutoff definition to predict successful parathyroidectomy in secondary and tertiary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32811697" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Critical analysis of the intraoperative parathyroid hormone decrease during parathyroidectomy for secondary and tertiary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30037429" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Stricter ioPTH criterion for successful parathyroidectomy in stage III CKD patients with primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17522522" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19529955" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing in guiding patients with a negative sestamibi scan for minimally invasive parathyroidectomy--a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8661845" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Side localization of parathyroid adenomas by simplified intraoperative venous sampling for parathyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20372897" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Bilateral internal jugular venous sampling for parathyroid hormone determination in patients with nonlocalizing primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23177271" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cryopreservation of parathyroid tissue: an illustrated technique using the cleveland clinic protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19717037" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : National trends in parathyroid surgery from 1998 to 2008: a decade of change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20130870" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Removal of autografted parathyroid tissue for recurrent renal hyperparathyroidism in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17111433" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Successful implant of long-term cryopreserved parathyroid glands after total parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18228092" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Viability of cryopreserved parathyroid tissue: when is continued storage versus disposal indicated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17516108" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Parathyroid subcutaneous pre-sternal transplantation after parathyroidectomy for renal hyperparathyroidism. Long-term graft function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9663244" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Autotransplantation of parathyroid glands into subcutaneous forearm tissue for renal hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10598201" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Subcutaneous forearm transplantation of autologous parathyroid tissue in patients with renal hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26054321" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Intramuscular and subcutaneous forearm parathyroid autograft hyperplasia in renal dialysis patients: A retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20800255" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Recurrent hyperparathyroidism and forearm parathyromatosis after total parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16415409" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Parathyroid graft function after presternal subcutaneous autotransplantation for renal hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12410355" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Total parathyroidectomy without autotransplantation as a standard procedure in the treatment of secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25643126" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pathophysiology and treatment of nonfamilial hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27741007" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Total Parathyroidectomy With Routine Thymectomy and Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism: Results of a Nonconfirmatory Multicenter Prospective Randomized Controlled Pilot Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9426420" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The current role of parathyroid cryopreservation and autotransplantation in parathyroid surgery: an institutional experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12430088" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Chronic kidney disease in the United States: an underrecognized problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17332726" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prevalence of chronic kidney disease and associated risk factors--United States, 1999-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19887829" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Outcomes in CKD: what we know and what we need to know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19432688" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of severe metastatic calcification in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15011912" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19142022" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Long-term outcome after total parathyroidectomy for the management of secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19566521" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Outcome of parathyroidectomy for patients with renal disease and hyperparathyroidism: predictors for recurrent hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17188148" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Less-than-subtotal parathyroidectomy increases the risk of persistent/recurrent hyperparathyroidism after parathyroidectomy in tertiary hyperparathyroidism after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The American Association of Endocrine Surgeons (AAES) guidelines for definitive management of primary hyperparathyroidism</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25162669" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19040989" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Evaluation for concomitant thyroid nodules and primary hyperparathyroidism in patients undergoing parathyroidectomy or thyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20822743" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Does routine use of ultrasound result in additional thyroid procedures in patients with primary hyperparathyroidism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12593724" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Is preoperative investigation of the thyroid justified in patients undergoing parathyroidectomy for hyperparathyroidism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15334393" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Synchronous thyroid pathology in patients presenting with primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17512273" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Use of preoperative parathyroid fine-needle aspiration and parathormone assay in the primary hyperparathyroidism with concomitant thyroid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8908448" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Association of primary hyperparathyroidism and non-medullary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863944" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Thyroid evaluation in patients with primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16187914" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The impact of office neck ultrasonography on reducing unnecessary thyroid surgery in patients undergoing parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17274751" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Preoperative evaluation of thyroid pathology in patients with primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24633247" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Co-existent thyroid disease in patients treated for primary hyperparathyroidism: implications for clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10779061" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Thyroid pathology associated with primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10595598" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Prevalence of primary hyperparathyroidism in 13387 patients with thyroid diseases, newly diagnosed by screening of serum calcium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19855263" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The usefulness of preoperative dual-phase 99mTc MIBI-scintigraphy and IO-PTH assay in the treatment of secondary and tertiary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17294211" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Usefulness of preoperative Tc-mibi parathyroid scintigraphy in secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16470331" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Sensitivity and utility of parathyroid scintigraphy in patients with primary versus secondary and tertiary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18953601" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Prolonged hospital stay after parathyroidectomy for secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321403" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Total parathyroidectomy under local anaesthesia for renal hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19533223" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Endoscopic total parathyroidectomy and partial parathyroid tissue autotransplantation for patients with secondary hyperparathyroidism: a new surgical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18726112" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Minimally invasive video-assisted subtotal parathyroidectomy with thymectomy for secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20095017" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Resection of ectopic mediastinal parathyroid glands with the da Vinci robotic system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15828905" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Surgical indications and procedures of parathyroidectomy in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16680589" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Total parathyroidectomy without autotransplantation for renal hyperparathyroidism: experience with a qPTH-controlled protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19460500" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Evaluation of thyroid disease in kidney transplantation candidates: management and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28949797" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Unplanned 30-Day Readmissions after Parathyroidectomy in Patients with Chronic Kidney Disease: A Nationwide Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30082137" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Quality of life after surgery in secondary hyperparathyroidism, comparing subtotal parathyroidectomy with total parathyroidectomy with immediate parathyroid autograft: Prospective randomized trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
